{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:16:49Z","timestamp":1792617409454,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Plasma biomarkers of dementia, including phosphorylated tau (p-tau217), offer promise as tools for diagnosis, stratification for clinical trials, monitoring disease progression, and assessing the success of interventions in those living with Alzheimer\u2019s disease. However, currently, it is unknown whether these dementia biomarker levels vary with the time of day, which could have implications for their clinical value. In two protocols, we studied 38 participants (70.8\u2009\u00b1\u20097.6 years; mean\u2009\u00b1\u2009SD) in a 27-h laboratory protocol with either two samples taken 12\u2009h apart or 3-hourly blood sampling for 24\u2009h in the presence of a sleep\u2013wake cycle. The study population comprised people living with mild Alzheimer\u2019s disease (PLWA,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20098), partners\/caregivers of PLWA (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096) and cognitively intact older adults (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924). Single-molecule array technology was used to measure phosphorylated tau (p-tau217) (ALZpath), amyloid-beta 40 (A\u03b240), amyloid-beta 42 (A\u03b242), glial fibrillary acidic protein, and neurofilament light (NfL) (Neuro 4-Plex E). Analysis with a linear mixed model (SAS, PROC MIXED) revealed a significant effect of time of day for p-tau217, A\u03b240, A\u03b242, and NfL, and a significant effect of participant group for p-tau217. For p-tau217, the lowest levels were observed in the morning upon waking and the highest values in the afternoon\/early evening. The magnitude of the diurnal variation for p-tau217 was similar to the reported increase in p-tau217 over one year in amyloid-\u03b2-positive mild cognitively impaired people. Currently, the factors driving this diurnal variation are unknown and could be related to sleep, circadian mechanisms, activity, posture, or meals. Overall, this work implies that the time of day of sample collection may be relevant in the implementation and interpretation of plasma biomarkers in dementia research and care.\n                  <\/jats:p>","DOI":"10.1038\/s41398-024-03084-7","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T07:03:29Z","timestamp":1726211009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["P-tau217 and other blood biomarkers of dementia: variation with time of day"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0422-4872","authenticated-orcid":false,"given":"Ciro","family":"della Monica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Revell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Atzori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-8357","authenticated-orcid":false,"given":"Rhiannon","family":"Laban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7828-3122","authenticated-orcid":false,"given":"Simon S.","family":"Skene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Hassanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Nilforooshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5314-1008","authenticated-orcid":false,"given":"Derk-Jan","family":"Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"3084_CR1","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1002\/alz.13455","volume":"19","author":"K Blennow","year":"2023","unstructured":"Blennow K, Galasko D, Perneczky R, Quevenco FC, van der Flier WM, Akinwonmi A, et al. The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2023;19:5805\u201316.","journal-title":"Alzheimers Dement"},{"key":"3084_CR2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12068","volume":"16","author":"Alzheimer's Association Report.","year":"2020","unstructured":"Alzheimer's Association Report. 2020 Alzheimeras disease facts and figures. Alzheimers Dement. 2020;16:391\u2013460.","journal-title":"Alzheimers Dement"},{"key":"3084_CR3","first-page":"567","volume":"9","author":"T Bittner","year":"2022","unstructured":"Bittner T. Editorial: What are the remaining challenges before blood-based biomarkers for Alzheimer\u2019s disease can be used in clinical practice? J Prev Alzheimers Dis. 2022;9:567\u20138.","journal-title":"J Prev Alzheimers Dis"},{"key":"3084_CR4","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9:197\u2013210.","journal-title":"J Prev Alzheimers Dis"},{"key":"3084_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"3084_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"3084_CR7","first-page":"398","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8:398\u2013410.","journal-title":"J Prev Alzheimers Dis"},{"key":"3084_CR8","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvado G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, et al. Prediction of longitudinal cognitive decline in preclinical Alzheimer disease using plasma biomarkers. JAMA Neurol. 2023;80:360\u20139.","journal-title":"JAMA Neurol"},{"key":"3084_CR9","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","volume":"79","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79:1250\u20139.","journal-title":"JAMA Neurol"},{"key":"3084_CR10","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/alz.13528","volume":"20","author":"MS Woo","year":"2024","unstructured":"Woo MS, Tissot C, Lantero-Rodriguez J, Snellman A, Therriault J, Rahmouni N, et al. Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-beta positive individuals. Alzheimers Dement. 2024;20:1166\u201374.","journal-title":"Alzheimers Dement"},{"key":"3084_CR11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1164\/rccm.201807-1289LE","volume":"198","author":"HJ Durrington","year":"2018","unstructured":"Durrington HJ, Gioan-Tavernier GO, Maidstone RJ, Krakowiak K, Loudon ASI, Blaikley JF, et al. Time of day affects eosinophil biomarkers in asthma: implications for diagnosis and treatment. Am J Respir Crit Care Med. 2018;198:1578\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"3084_CR12","doi-asserted-by":"crossref","unstructured":"Ravindran GKK, della Monica C, Atzori G, Lambert D, Hassanin H, Revell V, et al. Three contactless sleep technologies compared to actigraphy and polysomnography in a heterogenous group of older men and women in a model of mild sleep disturbance: a sleep laboratory study. JMIR Mhealth Uhealth. 2023;11:46338.","DOI":"10.2196\/46338"},{"key":"3084_CR13","doi-asserted-by":"crossref","unstructured":"Ravindran KKG, della Monica C, Atzori G, Lambert D, Hassanin H, Revell V, et al. Contactless and longitudinal monitoring of nocturnal sleep and daytime naps in older men and women: a digital health technology evaluation study. Sleep. 2023;46:zsad194.","DOI":"10.1093\/sleep\/zsad194"},{"key":"3084_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/clockssleep6010010","volume":"6","author":"C della Monica","year":"2024","unstructured":"della Monica C, Ravindran KK, Atzori G, Lambert DJ, Rodriguez T, Mahvash-Mohammadi S, et al. A protocol for evaluating digital technology for monitoring sleep and circadian rhythms in older people and people living with dementia in the community. Clocks Sleep. 2024;6:129\u201355.","journal-title":"Clocks Sleep"},{"key":"3084_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1017\/S1041610297004754","volume":"9","author":"DW Molloy","year":"1997","unstructured":"Molloy DW, Standish TI. A guide to the standardized mini-mental state examination. Int Psychogeriatr. 1997;9:87\u201394.","journal-title":"Int Psychogeriatr"},{"key":"3084_CR16","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1002\/alz.13157","volume":"19","author":"M Bilgel","year":"2023","unstructured":"Bilgel M, An Y, Walker KA, Moghekar AR, Ashton NJ, Kac PR, et al. Longitudinal changes in Alzheimer\u2019s-related plasma biomarkers and brain amyloid. Alzheimers Dement. 2023;19:4335\u201345.","journal-title":"Alzheimers Dement"},{"key":"3084_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41531-023-00447-7","volume":"9","author":"Y Tang","year":"2023","unstructured":"Tang Y, Han L, Li S, Hu T, Xu Z, Fan Y, et al. Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia. NPJ Parkinsons Dis. 2023;9:23.","journal-title":"NPJ Parkinsons Dis"},{"key":"3084_CR18","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonatis E, et al. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer\u2019s disease pathology. medRxiv: 2023.07.11.23292493 [Preprint]. 2023 [cited 2023 Nov 7]. Available from: https:\/\/doi.org\/10.1101\/2023.07.11.23292493","DOI":"10.1101\/2023.07.11.23292493"},{"key":"3084_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","volume":"68","author":"RJ Bateman","year":"2007","unstructured":"Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666\u20139.","journal-title":"Neurology"},{"key":"3084_CR20","doi-asserted-by":"publisher","first-page":"e89998","DOI":"10.1371\/journal.pone.0089998","volume":"9","author":"JA Dobrowolska","year":"2014","unstructured":"Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, et al. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One. 2014;9:e89998.","journal-title":"PLoS One"},{"key":"3084_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13024-017-0161-4","volume":"12","author":"BP Lucey","year":"2017","unstructured":"Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ. Diurnal oscillation of CSF Abeta and other AD biomarkers. Mol Neurodegener. 2017;12:36.","journal-title":"Mol Neurodegener"},{"key":"3084_CR22","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"3084_CR23","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain. 2020;143:3234\u201341.","journal-title":"Brain"},{"key":"3084_CR24","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1002\/alz.13163","volume":"19","author":"H Huber","year":"2023","unstructured":"Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, et al. Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake\u2014a pilot intervention study in healthy adults. Alzheimers Dement. 2023;19:5531\u201340.","journal-title":"Alzheimers Dement"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03084-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03084-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T07:05:07Z","timestamp":1726211107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03084-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3084"],"URL":"https:\/\/doi.org\/10.1038\/s41398-024-03084-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.12.11.23299805","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The other authors declare that they have no conflicts of interest related to this research.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"373"}}